Will NIH Eliminate The Unpopular “Two Strikes You’re Out” Grant Review Policy?

By Bouvier Grant Group

We stay current on NIH happenings and would be delighted to keep you informed.

In January 2009, NIH instituted a policy to sunset A2 applications, i.e. to eliminate a second resubmission. Since, investigators submit a grant application (A0) and if the application is unfunded they may submit one revised application (A1), and no more (previously, one could resubmit twice). This policy has been detested among research scientists since its inception and NIH has heard an earful of complaints about it. NIH spoke out recently on this topic. Will they consider eliminating the wildly unpopular policy? The short answer: Not bloody likely.

In a recent blog post, Sally Rockey gives some data NIH has compiled on this policy. One of the goals of the policy was to reduce the time to award, and in fact the time from A0 submission to award has been reduced from 93 weeks to 56 weeks by this policy. It is conventional wisdom that NIH grant applications, if funded, tend to be successful on their final submission, with very few succeeding as an A0. Yet surprisingly, since the policy went into effect, the proportion of funded A0 applications as compared to A1 apps has increased.

One major complaint of the policy is that it favors established investigators over new investigators. The data do not appear to support this idea, because the time-to-award for new applicants is not appreciably longer than for the entire population.

In response to the suggestion that NIH allow A2 applications only from those investigators whose apps fall just outside the payline, NIH modeled the potential impact of such a policy using FY11 data. From their model, NIH concluded that the result would be to shift awards from A0 and A1 apps toward A2 apps, which was what the policy was designed to avoid to begin with (see original blog post for details of their method.)

Rockey concludes: “Overall, these data indicate that the policy to sunset A2 applications continues to achieve the stated goals of enabling NIH to fund as much meritorious science as possible in as short a time period as possible. Any revision to the policy to allow additional resubmissions of all or a subset of A2 applications will displace equally meritorious A0 and A1 applications, and increase the time to award for many applications. For these reasons, we have decided to continue the policy in its current form.”

Sorry folks, it’s here to stay.

Dr. Meg Bouvier

Author:
Dr. Meg Bouvier

Margaret Bouvier received her PhD in 1995 in Biomedical Sciences from the Mount Sinai School of Medicine. After an NINDS post-doctoral fellowship, she worked as a staff writer for long-standing NIH Director Dr. Francis Collins in the Office of Press, Policy, and Communications for the Human Genome Project and NHGRI. Since 2007, Meg has specialized in editing and advising on NIH submissions, and began offering virtual courses in 2015. She's recently worked with more than 40% of the nation's highest-performing hospitals*, four of the top 10 cancer hospitals, three of the top five medical schools for research, and 14 NCI-designated cancer centers. Her experience at NIH as both a bench scientist and staff writer greatly informs her approach to NIH grantwriting. She has helped clients land over half a billion in federal funding. Bouvier Grant Group is a woman-owned small business.

*Our clients include 9 of the top 22 hospitals as recognized by the 2023/24 US News & World Report honor roll

Categories:
Related posts

You May Also Be Interested In

Bouvier Grant Group logo white
We read all NIH notices for our clients. When you join our mailing list, we’ll pass along important changes directly to your inbox, as well as opportunities to improve your grantsmanship skills.
Primary Position
Lead Source

Wait!

Subscribe to our monthly newsletter for the latest NIH news, grantwriting tips, and more.

NIH October 2023 Newsletter cover